Professional Reference articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.
Synonym: impotence (no longer used, as it implies failure)
Erectile dysfunction (ED) used to be called impotence. It is the inability to attain and maintain an erection sufficient for satisfactory sexual performance. Although a benign disorder, it can have a significant impact on the quality of life of sufferers, partners and families. It is important also to consider the physical and psychosocial health of the person who has the condition.[1, 2]Patients should be properly assessed and investigated before embarking on treatment.
- The incidence and prevalence is high worldwide.
- The first large-scale community study - the Massachusetts Male Ageing Study - showed that 52% of men (aged 40-70 years) were affected at some time (mild 17%; moderate 25%; severe 10%).
- A Cologne study reported that ED was the most prevalent of the male sexual dysfunctions (prevalence age 30-80 years) at 19.2% as compared to 31% for all types of male sexual dysfunction. This study equates to about 26 new cases annually per 1,000 men. Whichever study, country or methodology is used, this is clearly a significant condition likely to present regularly to a GP, on average between 1 and 4 times per month. Significant media interest has led more men to seek help for ED.
- There is in all studies a steep age-related increase. The Cologne study found that of men aged 30-80 years, the prevalence rose from 2.3% at age 30 to 53.4% at age 80.
- Only about 10-20% of patients with ED are believed to have a solely psychogenic cause but psychogenic factors are often present in those who are diagnosed as having a physical cause.
Risk factors for erectile dysfunction
ED shares risk factors with cardiovascular disease (CVD).Screening for CVD is a cost-effective method of secondary prevention for CVD in men presenting with ED.The following are all associated with both CVD and ED:
- Lack of exercise
- Metabolic syndrome
- Diabetes mellitus
It is important that underlying diseases and causative conditions do not go undetected. There are many different causes, including many drugs:
- Atherosclerosis (approximately 50% of cases).
- Diabetes mellitus.
- Surgery or radiotherapy to the pelvis or retroperitoneum - eg, radical prostatectomy (25-75% of these men have ED).
- Parkinson's disease, stroke.
- Multiple sclerosis (MS).
- Traumatic brain injury (causing hypothalamic-pituitary deficiency).
- Cerebrovascular disease.
- Intervertebral disc disease.
- Spinal cord disease or injury.
- Peripheral neuropathy.
- Diabetes mellitus.
- Surgery (for example, of pelvis or retroperitoneum).
- Thyroid disease.
- Cushing's disease.
- Peyronie's disease.
- Micropenis and other penile anomalies.
- Antidepressants: both tricyclics and selective serotonin reuptake inhibitors (SSRIs).
- Antipsychotics: phenothiazines, risperidone.
- Hormonal agents: cyproterone acetate, luteinising hormone-releasing hormone analogues - those used in the treatment of prostate cancer.
- Anticonvulsants: phenytoin, carbamazepine.
- Recreational drugs.
- H2 antagonists cimetidine and ranitidine.
- General (disorders of sexual intimacy, lack of arousability).
- Situational (partner, performance or stress).
- One study found that maintaining a regular frequency of intercourse can reduce the risk of ED for males aged 30-75 years.
- Generalised anxiety states.
- Alcoholism (the relationship with alcohol is not straightforward). A Chinese study suggested an additive association with smoking. It reported that drinking three or more standard alcoholic drinks per week might reduce sexual satisfaction and impair erectile function in current smokers and might have less effect in those who had never smoked.A meta-analysis showed a protective effect of alcohol at some levels of consumption).
- Sexual history. Validated questionnaires to assess sexual function and the effects of treatment are available - for example, the International Index of Erectile Function (IIEF).The following should be covered:
- Current and past sexual relationships.
- Current emotional status.
- Erectile symptoms: onset and duration.
- Previous advice or treatments.
- Quality of erections (erotic and morning erections).
- Arousal, ejaculation and orgasmic difficulties.
- Medical and past medical history:
- This may include detail of any relevant conditions (see the causes of erectile dysfunction, above).
- Medication should be listed.
History suggesting psychogenic causes
- Sudden onset.
- Early collapse of erection.
- Self-stimulated or waking erections.
- Premature ejaculation or inability to ejaculate.
- Problems or changes in a relationship.
- Major life events.
- Psychological problems.
History suggesting organic causes
- Gradual onset.
- Normal ejaculation.
- Normal libido (except hypogonadal men).
- Risk factor in medical history (cardiovascular, endocrine or neurological).
- Operations, radiotherapy, or trauma to the pelvis or scrotum.
- A current drug recognised as associated with ED.
- Smoking, high alcohol consumption, use of recreational or bodybuilding drugs
The examination should be focused and performed on all patients:
- Genitourinary examination (it is necessary to detect, for example, Peyronie's disease, gonadal anomalies, retractile foreskin).
- Attention to any endocrine (including testicular size and secondary sexual characteristics), neurological or vascular causes as appropriate, especially if indicated by the history.
- Pulse (including peripheral pulses) and blood pressure if recent readings are not available. Because ED shares risk factors with CVD, a full cardiovascular assessment should be performed.
- Rectal examination in patients over the age of 50 years.
Investigations will be directed by the history and clinical findings.
- The European Association of Urology and the British Society of Sexual Medicine suggest:
- Fasting glucose or HbA1c and lipid profile for all patients (if not assessed in the previous 12 months).
- Morning sample of total testosterone (free testosterone if available, as it is more reliable in detection of hypogonadism).
- Further tests (for example, PSA) only in selected patients.
- Addition of follicle-stimulating hormone (FSH), luteinising hormone (LH), and prolactin when low testosterone is detected.
- Other specific investigations may be indicated and are appropriately arranged by urologists. Indications for referral for these further tests are given below. Further tests include:
- Nocturnal penile tumescence and rigidity studies.
- Vascular studies:
- Duplex ultrasound cavernous arteries.
- Intracavernous vasoactive drug injection.
- Dynamic infusion cavernosography.
- Arteriography (internal pudendal).
- Neurological studies.
- Endocrinology work-up.
- Specialist psychodiagnostic evaluation.
Indications for referral
The following should be referred for further assessment or specific diagnostic tests:
- Endocrine abnormality.
- Referral for underlying organic disease as appropriate - eg, cardiovascular or neurological.
- Young patients who have had pelvic or perineal trauma.
- Penile disorders or deformities requiring possible surgical correction.
- Complex cases (whether psychiatric, cardiovascular, psychosexual or endocrine).
- If a patient of partner requests referral or special tests.
- The main aim of management is to diagnose and treat the cause of ED when possible.
- Associated modifiable or reversible factors (lifestyle, drug-related factors) should be considered as well as specific therapies.
- Most often it cannot be cured but, where appropriate, curative therapies should be offered.
- Treatments will be selected, therefore, according to efficacy, safety, invasiveness, cost and patient preference.
- With increasing longevity, the treatment of ED in the elderly has assumed greater importance. Hypogonadism should be treated with testosterone replacement, regardless of age.
- A flow chart or algorithm can be used to assist treatment plans.
Data from basic science and clinical studies have identified a link between the occurrence of ED and a number of lifestyle factors, such as smoking, obesity, alcohol consumption and lack of physical activity.Cycling for more than three hours per week has been identified as an independent risk factor for ED. Large-scale trials are needed to assess the place of lifestyle modification in the management of ED.
Treating the cause
The following are regarded as curable causes for ED, which can be treated:
- Hormonal causes:
- Testicular failure - treat with testosterone.
- Pituitary or hypothalamic causes - treat the underlying causes; for example, pituitary tumours causing hyperprolactinaemia.
- Post-traumatic arteriogenic ED in young patients:
- Surgery following pelvic or perineal trauma has a 60-70% success rate.
- This requires proper diagnostic work-up (including duplex ultrasound and arteriography).
- Psychosexual causes:
- Management includes the management of any specific underlying psychological problem.
- Psychosexual therapy:
- See separate Sex Therapy and Counselling article.
- A meta-analysis confirmed the effectiveness of group psychotherapy in the treatment of ED and that psychological interventions were as effective as vacuum devices and local injections.
- Psychological therapy is most effective when appropriately targeted.
- Drug treatments (eg, the phosphodiesterase type-5 inhibitors sildenafil, tadalafil, vardenafil and avanfil) may be effective and sometimes need only be used short-term.
First-line therapy for ED
Phosphodiesterase inhibitors (sildenafil, tadalafil, vardenafil and avanafil) improve the relaxation of smooth muscle. Efficacy of the drug is dependent on release of nitric oxide from the nerve terminals of the cavernosal nerve
Use of high-dose sildenafil after radical prostatectomy (RP) has been suggested to be associated with preservation of smooth muscle within the corpora cavernosa and daily use results in a greater return of spontaneous normal erectile function after RP compared to placebo in patients who were fully potent before surgery.
Sildenafil, tadalafil, vardenafil and avanafil are contra-indicated in patients receiving nitrates (because of possible severe hypotension, which may lead to acute myocardial infarction, stroke and even death).
- Phosphodiesterase inhibitors are also contra-indicated in patients in whom vasodilation or sexual activity are inadvisable, and where there is previous history of non-arteritic anterior ischaemic optic neuropathy, hypotension (avoid if systolic blood pressure is below 90 mm Hg and there is recent stroke, unstable angina or myocardial infarction).
- There are no meta-analyses to compare the four preparations, so choice will depend on personal preference of the patient and frequency of intercourse:
- Improves erectile function and is generally well tolerated.
- Efficacy is reduced after fatty meals.
- 50 mg is the recommended starting dose (change according to response).
- Adverse events are rare and the drop-out rate similar to placebo.
- Has a longer half-life - therefore, potentially, a longer action and therefore greater spontaneity (effective after 30 minutes, with peak efficacy at two hours and lasting up to 36 hours).
- Start at 10 mg (change according to response).
- Adverse events and drop-outs similar to above.
- Better results in subgroups which are difficult to treat.
- Effective after 30 minutes.
- Useful in subgroups which are difficult to treat.
- Its effect is reduced by a fatty meal but it has less interaction with food. A rapidly absorbed orodispersible preparation has now been made available which is more rapdily absorbed.
- Effective after 30 minutes.
- High selection for phosphodiesterase inhibition minimises the risk of side-effects.
- Effect may be delayed when administered with food but can be taken with or without food.
Increasing numbers of products are available via the internet. They are all unlicensed and many have adverse effects. They include yohimbine, maca, horny goatweed and gingko biloba.
- An external cylinder is fitted over the penis to allow air to be pumped out, resulting in engorgement of penis with blood.
- Studies suggest that whilst two thirds of patients are unable to achieve ejaculation, 74% are able to achieve orgasm.
- They work best when there is a motivated, interested and understanding partner. They may be the treatment of choice in well-informed older patients and in those with comorbidities precluding use of drugs or invasive methods.
- Adverse events include pain, petechiae, bruising and numbness.
Second-line therapy for ED
Intraurethral alprostadil (prostaglandin E1)
- This is inserted as a medicated pellet called MUSE® into the urethral meatus and produces an erection after about 15 minutes.
- Barrier contraception must be used if the partner is pregnant.
- 30-65.9% of patients achieve erections sufficient for intercourse.
- However, it is less effective than intracavernous injections.
- The most common side-effect is mild penile pain (29-41% of patients).
Topical alprostadil (prostaglandin E1)
- A cream is licensed for topical use.
- It should be applied 5-30 minutes before intercourse.
- It is administered using a plunger which delivers the cream to the tip of the penis and surrounding skin.
Intracavernosal alprostadil (prostaglandin E1)
- Injections of alprostadil are given into the corpora cavernosa to produce an erection. It is licensed in the UK for a maximum dose of 40 micrograms. The duration of erection depends on the dose.
- Efficacy rates for intracavernous alprostadil of >70% in the general population have been reported and it is often effective for those men who do not respond to oral drug treatment.
- Penile pain (50% of patients) is usually mild but a significant number of men stop using this method because of this side-effect.
- If priapism occurs with alprostadil:
- The patient should be referred urgently to hospital.
- Patients are advised to seek medical advice if the erection has lasted longer than four hours.
- Treatment should not be delayed for more than six hours. Initial treatment is by aspiration of blood from the corpus cavernosum.
- If this is unsuccessful, cautious intracavernosal injection of a sympathomimetic (eg, phenylephrine or adrenaline (epinephrine) may be required).
- If sympathomimetics are unsuccessful, urgent surgical referral is required (possibly including shunt procedure).
Third-line therapy for ED
- Semi-rigid, malleable or inflatable devices surgically inserted to produce an erect state. Most patients prefer the three-piece inflatable penile prosthesis which includes a separate reservoir placed in the abdominal cavity.
- Prostheses should be considered in patients whose ED has an organic cause and who are unwilling to consider, fail to respond to, or are unable to continue with medical treatment or external devices.
Low-intensity shock-wave therapy has shown promising results in trials in patients resistant to other treatments.
NHS or private prescription?
In England, Scotland and Wales, sildenafil can be prescribed on the NHS for any man with ED. In Northern Ireland, it is on the Red List, which means that responsibility for prescribing should remain with a hospital specialist.
The other phosphodiesterase inhibitors and alprostadil can only be prescribed on the NHS for men who:
- Have diabetes, MS, Parkinson's disease, poliomyelitis, prostate cancer, severe pelvic injury, single-gene neurological disease, spina bifida, or spinal cord injury.
- Are receiving dialysis for chronic kidney disease.
- Have had radical pelvic surgery, prostatectomy, or a kidney transplant.
- Treatment should also be available from specialist services (under local agreement) when the condition is causing severe distress. The criteria for severe distress include:
- Significant disruption to normal social and occupational activities.
- A marked effect on mood, behaviour, social and environmental awareness.
- A marked effect on interpersonal relationships.
If the patient does not fit these criteria, a private prescription can be issued.
Did you find this information useful?
Further reading & references
- Shridharani AN, Brant WO; The treatment of erectile dysfunction in patients with neurogenic disease. Transl Androl Urol. 2016 Feb 5(1):88-101. doi: 10.3978/j.issn.2223-4683.2016.01.07.
- Guidelines on Priapism; European Association of Urology (2015)
- Muneer A, Kalsi J, Nazareth I, et al; Erectile dysfunction. BMJ. 2014 Jan 27 348:g129. doi: 10.1136/bmj.g129.
- Lin CS, Xin ZC, Wang Z, et al; Stem cell therapy for erectile dysfunction: a critical review. Stem Cells Dev. 2012 Feb 10 21(3):343-51. doi: 10.1089/scd.2011.0303. Epub 2011 Sep 7.
- Guidelines on Male Sexual Dysfunction: Erectile dysfunction and premature ejaculation; European Association of Urology (2015)
- San Martin C, Simonelli C, Sonksen J, et al; Perceptions and opinions of men and women on a man's sexual confidence and its relationship to ED: results of the European Sexual Confidence Survey. Int J Impot Res. 2012 Nov-Dec 24(6):234-41. doi: 10.1038/ijir.2012.23. Epub 2012 Jun 21.
- Nehra A, Jackson G, Miner M, et al; Diagnosis and Treatment of Erectile Dysfunction for Reduction of Cardiovascular Risk. J Urol. 2013 Jan 9. pii: S0022-5347(13)00009-8. doi: 10.1016/j.juro.2012.12.107.
- Javaroni V, Neves MF; Erectile dysfunction and hypertension: impact on cardiovascular risk and treatment. Int J Hypertens. 2012 2012:627278. doi: 10.1155/2012/627278. Epub 2012 May 9.
- Hirooka N, Lapp DP; Erectile dysfunction as an initial presentation of diabetes discovered by taking sexual history. BMJ Case Rep. 2012 May 8 2012. pii: bcr1220115289. doi: 10.1136/bcr.12.2011.5289.
- Keller J, Chen YK, Lin HC; Hyperthyroidism and erectile dysfunction: a population-based case-control study. Int J Impot Res. 2012 Nov-Dec 24(6):242-6. doi: 10.1038/ijir.2012.24. Epub 2012 Jun 21.
- Qin Z, Tian B, Wang X, et al; Impact of frequency of intercourse on erectile dysfunction: a cross-sectional study in Wuhan, China. J Huazhong Univ Sci Technolog Med Sci. 2012 Jun 32(3):396-9. doi: 10.1007/s11596-012-0068-9. Epub 2012 Jun 9.
- Perelman MA; Erectile dysfunction and depression: screening and treatment. Urol Clin North Am. 2011 May 38(2):125-39. doi: 10.1016/j.ucl.2011.03.004.
- Lee AC, Ho LM, Yip AW, et al; The effect of alcohol drinking on erectile dysfunction in Chinese men. Int J Impot Res. 2010 Jul-Aug 22(4):272-8. doi: 10.1038/ijir.2010.15. Epub 2010 Jun 17.
- Maiorino MI, Bellastella G, Esposito K; Lifestyle modifications and erectile dysfunction: what can be expected? Asian J Androl. 2015 Jan-Feb 17(1):5-10. doi: 10.4103/1008-682X.137687.
- Papagiannopoulos D, Khare N, Nehra A; Evaluation of young men with organic erectile dysfunction. Asian J Androl. 2015 Jan-Feb 17(1):11-6. doi: 10.4103/1008-682X.139253.
- Guidelines on the management of erectile dysfunction; British Society of Sexual Medicine (2009)
- Romanelli F, Sansone A, Lenzi A; Erectile dysfunction in aging male. Acta Biomed. 2010 81 Suppl 1:89-94.
- Lamina S, Agbanusi E, Nwacha RC; Effects of aerobic exercise in the management of erectile dysfunction: a meta analysis study on randomized controlled trials. Ethiop J Health Sci. 2011 Nov 21(3):195-201.
- Melnik T, Soares BG, Nasello AG; The effectiveness of psychological interventions for the treatment of erectile dysfunction: systematic review and meta-analysis, including comparisons to sildenafil treatment, intracavernosal injection, and vacuum devices. J Sex Med. 2008 Nov 5(11):2562-74. doi: 10.1111/j.1743-6109.2008.00872.x. Epub 2008 Jun 17.
- Fonagy P; Psychotherapy research: do we know what works for whom? Br J Psychiatry. 2010 Aug 197(2):83-5. doi: 10.1192/bjp.bp.110.079657.
- Corazza O, Martinotti G, Santacroce R, et al; Sexual enhancement products for sale online: raising awareness of the psychoactive effects of yohimbine, maca, horny goat weed, and Ginkgo biloba. Biomed Res Int. 2014 2014:841798. doi: 10.1155/2014/841798. Epub 2014 Jun 15.
- Pinsky MR, Chawla A, Hellstrom WJ; Intracavernosal therapy and vacuum devices to treat erectile dysfunction. Arch Esp Urol. 2010 Oct 63(8):717-25.
- Costa P, Potempa AJ; Intraurethral alprostadil for erectile dysfunction: a review of the literature. Drugs. 2012 Dec 3 72(17):2243-54. doi: 10.2165/11641380-000000000-00000.
- Moncada I, Cuzin B; Clinical efficacy and safety of Vitaros(c)/Virirec(c) (Alprostadil cream) for the treatment of erectile dysfunction. Urologia. 2015 Apr-Jun 82(2):84-92. doi: 10.5301/uro.5000116. Epub 2015 Mar 3.
- Srini VS, Reddy RK, Shultz T, et al; Low intensity extracorporeal shockwave therapy for erectile dysfunction: a study in an Indian population. Can J Urol. 2015 Feb 22(1):7614-22.
- Northern Ireland Regional Group on Specialist Medicines: Red Amber List; Interface Pharmacist Network Specialist Medicines, March 2016
Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. Patient Platform Limited has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.